ArticleAnnals of medicine and surgery (2012)2026
Unlocking synergistic potential: enhancing paclitaxel efficacy in combination with silibinin in breast cancer cell line through H19 LncRNA and P53/Bax/Bcl2 axis.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a major global health concern and the second most frequently diagnosed malignancy in women. Paclitaxel, a key chemotherapeutic agent, shows strong antineoplastic activity but is limited by toxicity and resistance. While combining paclitaxel with natural compounds is promising, the role of H19 lncRNA in mediating paclitaxel-silibinin synergy is not yet known. This study evaluates their combined efficacy via modulation of H19 lncRNA and the P53/Bax/Bcl2 apoptotic pathway. We investigated the chemosensitizing effect of silibinin, a flavonoid, in combination with paclitaxel in breast cancer cells. Drug interactions were analyzed using the Chou-Talalay combination index and cytotoxicity assessed by MTT assays. Apoptosis was measured through caspase-3/7 activity, and transcriptional changes in H19 lncRNA, P53, Bax, and Bcl-2 were quantified by real-time PCR. Silibinin and paclitaxel exhibited a synergistic effect, reducing paclitaxel IC50 and increasing cytotoxicity. Co-treatment enhanced caspase-3/7 activation, upregulated pro-apoptotic P53 and Bax, and downregulated anti-apoptotic Bcl-2 and oncogenic H19 lncRNA. Silibinin alone caused a threefold reduction in H19 expression, whereas paclitaxel alone had minimal effect. Silibinin potentiates paclitaxel cytotoxicity by suppressing H19 transcription, offering a potential strategy to overcome paclitaxel resistance. The combination promotes apoptosis via caspase activation, highlighting a novel synergistic therapeutic approach in breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.